Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD.

Nora DrickJan FugeBenjamin SeeligerMilan SpethJens Vogel-ClaussenTobias WelteHendrik Suhling

Published in: ERJ open research (2022)

Anti-eosinophilic therapy with interleukin-5/interleukin-5-receptor antibodies shows clinical efficacy in patients with SEA and COPD comparable to treatment response in patients with SEA alone.

Keyphrases

chronic obstructive pulmonary disease
lung function
air pollution
cystic fibrosis
early onset
stem cells
binding protein
bone marrow
smoking cessation